Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeeking Alpha • 09/05/25
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/02/25
Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo InflectionSeeking Alpha • 08/28/25
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis ClinicsGlobeNewsWire • 08/21/25
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/07/25
Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth ConferenceGlobeNewsWire • 08/06/25
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis OrganizationGlobeNewsWire • 08/04/25
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business HighlightsGlobeNewsWire • 07/31/25
Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 07/16/25
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 07/16/25
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual ConferenceGlobeNewsWire • 07/08/25
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of NephrologyGlobeNewsWire • 06/04/25
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025GlobeNewsWire • 05/28/25
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025GlobeNewsWire • 05/27/25
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor ConferenceGlobeNewsWire • 05/13/25
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top EstimatesZacks Investment Research • 05/08/25
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/08/25
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 05/01/25
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business HighlightsGlobeNewsWire • 05/01/25